Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib in Colorectal Cancer Following Adjuvant Chemotherapy
NCT00031863Phase 3Completed
- Sponsor
- CRUK & UCL Cancer Trials Centre
- Start
- Feb 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rofecoxib in colorectal cancer (CRC) (4 arms), sponsored by CRUK & UCL Cancer Trials Centre. Primary endpoints: Overall Survival at 5 years and Relapse-Free Survival at 5 years. Started Feb 2001; status: completed.
02
Drugs
rofecoxib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00031863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031863.